Welcome to our dedicated news page for OREXO AB SP/ADR (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on OREXO AB SP/ADR.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OREXO AB SP/ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OREXO AB SP/ADR's position in the market.
Orexo AB held its annual general meeting on April 26, 2024, where key decisions were made regarding the board of directors, auditor fees, nomination committee, financial statements, share issuance, share repurchase, and the adoption of long-term incentive programs. James Noble was elected as the chairman of the board, and Ernst & Young Aktiebolag was re-elected as the auditor. The meeting also approved the income statement and balance sheets for the financial year 2023, with no dividend declared for that year. The board was discharged from liability for the same year. Additionally, the board was authorized to issue new shares and repurchase and transfer existing shares, with specific limits and purposes outlined. Two long-term incentive programs, LTIP 2024 and LTIP Stay-on 2024, were adopted for selected employees within the Orexo group.
